Influenza HA (126-138) is a influenza virus hemagglutinin (HA) peptide comprising amino acids 126-138, induces thymic and peripheral T-cell apoptosis.
Influenza HA 126-138 is a synthetic peptide fragment derived from the hemagglutinin (HA) protein of the influenza virus, specifically corresponding to amino acid residues 126 through 138. As a well-characterized epitope region, this peptide holds significant importance in virology and immunology research, serving as a model for antigenic studies and molecular recognition processes. Its sequence represents a conserved portion of the HA protein, a critical viral surface glycoprotein responsible for host cell binding and membrane fusion during infection. The defined structure and immunological relevance of this peptide make it a valuable tool for dissecting host-pathogen interactions, antibody specificity, and vaccine design strategies within influenza research.
Epitope mapping: In the context of immunological investigations, the HA 126-138 peptide is widely utilized for epitope mapping studies. By providing a defined linear sequence from the hemagglutinin protein, it enables researchers to identify and characterize antibody binding sites, elucidate the fine specificity of humoral immune responses, and distinguish cross-reactive or subtype-specific epitopes. This application is essential for understanding the molecular basis of immune recognition, guiding the rational selection of antigenic targets for diagnostic or prophylactic purposes, and informing the design of next-generation influenza vaccines.
Antibody screening: The peptide serves as a critical reagent in antibody screening assays, such as enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance (SPR) studies. By immobilizing HA 126-138 on assay platforms, investigators can evaluate the binding affinity and specificity of monoclonal or polyclonal antibodies generated against influenza HA. This approach is instrumental in the development and validation of research-grade detection reagents, as well as in the assessment of immune responses in animal models or human samples exposed to the influenza virus.
Structural biology: HA 126-138 is frequently employed in structural studies aimed at unraveling the conformational determinants of antigen-antibody interactions. Its defined length and sequence allow for high-resolution analyses using techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. These investigations provide valuable insights into the molecular recognition mechanisms underlying immune defense, facilitate the rational engineering of antibody fragments, and contribute to the broader understanding of viral antigenicity.
T-cell response analysis: The peptide is also leveraged in the study of cellular immune responses, particularly for investigating T-cell epitope recognition. By using HA 126-138 in ex vivo or in vitro assays, researchers can stimulate and monitor the activation of specific T-cell populations, measure cytokine release, and assess the repertoire of T-cell receptors involved in influenza immunity. Such studies are fundamental for dissecting the cellular components of protective immune responses and for identifying candidate peptide epitopes suitable for inclusion in peptide-based vaccine formulations.
Peptide-based assay development: The defined biochemical properties of HA 126-138 make it suitable for incorporation into custom assay development workflows. Researchers utilize this peptide to optimize and validate protocols for peptide synthesis, purification, and functionalization, as well as to calibrate analytical platforms designed to detect or quantify influenza-specific immune responses. Its stability and sequence specificity support the establishment of robust experimental systems that advance both basic and applied research in virology, immunology, and vaccine development.
2. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More